Early Stage East is please to announce that Kelly Perdew, winner of the second season of NBC’s “The Apprentice,” will be the Keynote Speaker at the 10th annual Early Stage East Venture Conference to be held June 13th and 14th at the DuPont Country Club located in Wilmington, Delaware. In addition to being the winner of the second season of “The Apprentice,” Kelly is also an entrepreneur, author, television host, celebrity spokesperson and business leader. He is currently the managing director of Angel Venture Partners, a venture capital fund, and is working on several real estate projects, including 25 self-storage facilities and a 600-acre fishing and hunting preserve in Montana. Perdew is also the President of ProElite.com, a subsidiary of ProElite, Inc (PELE.PK) and an online social networking platform for mixed martial arts fans, fighters and organizations. Perdew, who served as a military intelligence officer for the U.S. Army, also lends his military knowledge to television viewers as host of the Military Channel’s series “GI Factory,” which explores military technology and history. Perdew is the author of Take Command: 10 Leadership Principles I Learned in the Military and Put to Work for Donald Trump, a book that explores the ties between Perdew’s military training and business success and provides advice to aspiring entrepreneurs or anyone embarking on a new career.

Prior to winning “The Apprentice,” Perdew was the chairman and co-founder of www.MotorPride.com, an online social network site for car, truck and motorcycle enthusiasts which Perdew sold to ZAG.com in 2006.


More Details

“ESE is a wonderful platform for young companies to get exposure to a wide range of investors and potential business leads,” said Dr. Nicolas Nicolaides, President of Morphotek, Inc. and presenter at Bio-Life-Tech 2002.

Morphotek is a subsidiary of Eisai, Inc. which discovers and develops monoclonal antibodies for oncology, inflammatory and infectious diseases through the use of a proprietary human antibody technology called Human MORPHODOMA®. The company has assembled a strong pipeline of lead products in the area of cancer, inflammation and infectious diseases. Morphotek’s most advanced programs are MORAb-003, in Phase I/II for ovarian cancer, and MORAb-009, in Phase I for pancreatic and lung cancer. There are several additional preclinical stage programs moving towards IND filing. Its partners to date have included world-renowned research laboratories and leading biopharmaceutical companies.


More Details